Sandoz gains rights to Graftskin:
This article was originally published in Clinica
Executive Summary
Organogenesis has granted Swiss pharmaceutical company Sandoz the licensing rights to Graftskin, its manufactured human skin product. Under the terms of the agreement, Sandoz will have exclusive worldwide rights to the product and will pay Organogenesis $37.5 million in equity investments, milestone payments and research support. The initial equity investment of $5 million will give Sandoz 1.6% of the outstanding shares of Massachusetts-based Organogenesis. Graftskin's PMA for venous stasis ulcers has been granted expedited review status by the US FDA.